- Home
- AGIO vs NAC Comparison
AGIO vs NAC Comparison
Compare AGIO & NAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- NAC
- Stock Information
- Founded
- AGIO 2007
- NAC 1998
- Country
- AGIO United States
- NAC France
- Employees
- AGIO N/A
- NAC N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- NAC Investment Managers
- Sector
- AGIO Health Care
- NAC Finance
- Exchange
- AGIO Nasdaq
- NAC Nasdaq
- Market Cap
- AGIO 1.4B
- NAC 1.6B
- IPO Year
- AGIO 2013
- NAC N/A
- Fundamental
- Price
- AGIO $39.23
- NAC $11.19
- Analyst Decision
- AGIO Buy
- NAC
- Analyst Count
- AGIO 6
- NAC 0
- Target Price
- AGIO $58.60
- NAC N/A
- AVG Volume (30 Days)
- AGIO 615.0K
- NAC 307.3K
- Earning Date
- AGIO 07-31-2025
- NAC 01-01-0001
- Dividend Yield
- AGIO N/A
- NAC 4.33%
- EPS Growth
- AGIO N/A
- NAC N/A
- EPS
- AGIO 11.45
- NAC N/A
- Revenue
- AGIO $37,035,000.00
- NAC N/A
- Revenue This Year
- AGIO $22.30
- NAC N/A
- Revenue Next Year
- AGIO $219.19
- NAC N/A
- P/E Ratio
- AGIO $3.39
- NAC N/A
- Revenue Growth
- AGIO 25.96
- NAC N/A
- 52 Week Low
- AGIO $23.42
- NAC $9.32
- 52 Week High
- AGIO $62.58
- NAC $11.21
- Technical
- Relative Strength Index (RSI)
- AGIO 70.51
- NAC 61.35
- Support Level
- AGIO $34.60
- NAC $11.16
- Resistance Level
- AGIO $40.06
- NAC $11.24
- Average True Range (ATR)
- AGIO 1.45
- NAC 0.05
- MACD
- AGIO 0.43
- NAC 0.00
- Stochastic Oscillator
- AGIO 88.98
- NAC 79.44
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.